TheraRadar
← Back
Data updated: Jun 28, 2026

ORBION PHARMS

Generics

ORBION PHARMS is a generic drug manufacturer focused on Neurology.

2007
Since
27
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

ORBION PHARMS's Key Drugs

ORBION PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ORBION PHARMS's Recent FDA Approvals

New NDA/BLA approvals for ORBION PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ORBION PHARMS's Therapeutic Areas

ORBION PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
5 drugs

ORBION PHARMS's Top Competitors

ORBION PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ORBION PHARMS Pipeline Snapshot

Active clinical trials for ORBION PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling